{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002733","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.535546+00:00","generated_at":"2026-06-07T02:27:53.890997+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Nkarta posts updated corporate presentation; no specific material updates in filing excerpt","bullets":["Company made available an updated corporate presentation dated January 2024.","Presentation focuses on NK cell engineering for cancer and autoimmune diseases.","Filed exhibit contains only a title slide; no financial data or milestones provided.","Presentation is furnished under Regulation FD and not filed with the SEC."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002733","json":"https://secwatch.observer/filing/0000950170-24-002733.json","markdown":"https://secwatch.observer/filing/0000950170-24-002733.md","text":"https://secwatch.observer/filing/0000950170-24-002733.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024002733/0000950170-24-002733-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024002733/nktx-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:27:53.890997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}